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STUDY QUESTION:What is the likelihood of identifying genetic or endocrine abnormalities in a group of boys with 46, XY who present
to a specialist clinic with a suspected disorder of sex development (DSD)?
SUMMARY ANSWER: An endocrine abnormality of the gonadal axis may be present in a quarter of cases and copy number variants
(CNVs) or single gene variants may be present in about half of the cases.
WHAT IS KNOWN ALREADY: Evaluation of 46, XY DSD requires a combination of endocrine and genetic tests but the prevalence of
these abnormalities in a sufﬁciently large group of boys presenting to one specialist multidisciplinary service is unclear.
STUDY, DESIGN, SIZE, DURATION: This study was a retrospective review of investigations performed on 122 boys.
PARTICIPANTS/MATERIALS, SETTING, METHODS: All boys who attended the Glasgow DSD clinic, between 2010 and 2015
were included in the study. The median external masculinization score (EMS) of this group was 9 (range 1–11). Details of phenotype, endo-
crine and genetic investigations were obtained from case records.
MAIN RESULTS AND THE ROLE OF CHANCE: An endocrine abnormality of gonadal function was present in 28 (23%) with a median
EMS of 8.3 (1–10.5) whilst the median EMS of boys with normal endocrine investigations was 9 (1.5–11) (P = 0.03). Endocrine abnormalities
included a disorder of gonadal development in 19 (16%), LH deﬁciency in 5 (4%) and a disorder of androgen synthesis in 4 (3%) boys. Of 43
cases who had array-comparative genomic hybridization (array-CGH), CNVs were reported in 13 (30%) with a median EMS of 8.5 (1.5–11).
Candidate gene analysis using a limited seven-gene panel in 64 boys identiﬁed variants in 9 (14%) with a median EMS of 8 (1–9). Of the 21
boys with a genetic abnormality, 11 (52%) had normal endocrine investigations.
LIMITATIONS, REASONS FOR CAUTION: A selection bias for performing array-CGH in cases with multiple congenital malformations
may have led to a high yield of CNVs. It is also possible that the yield of single gene variants may have been higher than reported if the investi-
gators had used a more extended gene panel.
WIDER IMPLICATIONS OF THE FINDINGS: The lack of a clear association between the extent of under-masculinization and pres-
ence of endocrine and genetic abnormalities suggests a role for parallel endocrine and genetic investigations in cases of suspected XY DSD.
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Introduction
A disorder of sex development (DSD) can present as a range of phe-
notypes, from slightly atypical genitalia to complete sex reversal and
despite advances in our understanding of the processes of sex deter-
mination and differentiation, the aetiology of 46, XY DSD remains elu-
sive in several cases (Ahmed & Rodie, 2010). Reaching a deﬁnitive
diagnosis is important in cases of DSD as it can enable genetic counsel-
ling to address issues such as aetiology andrecurrence risk for indivi-
duals and their families and it may also clarify management relating to
adrenal health, gonadal tumour risk and long-term fertility (Kyriakou
et al., 2015). An aetiological diagnosis was reported in 31% of cases of
severe hypospadias in 2001 (Boehmer et al., 2001) and, when using
the DSD classiﬁcation that was recommended a decade ago (Hughes
et al., 2006), a genetic diagnosis has been reported to be clear in over
80% of boys with a disorder of androgen synthesis (DAS; Morel et al.,
2011), about 40% of boys with a disorder of gonadal development
(DGD; Laino et al., 2014) and probably about 20% of boys with a sus-
pected disorder of androgen action (Ahmed et al., 2000a). In addition,
30% of DSD cases may have copy number variants (CNVs) on array-
comparative genomic hybridization (array-CGH; Baetens et al., 2014).
However, the extent of investigations performed and the selection of
cases that undergo investigations may vary extensively from one centre
to another (Rodie et al., 2011) and the yield of abnormalities may
depend on the approach adopted by the centre. The aim of the cur-
rent study was to gain an insight into the prevalence of genetic and
endocrine abnormalities in a contemporary cohort of 46, XY DSD
boys in the UK who were investigated systematically according to
recommendations of a recent expert group (Ahmed et al., 2016) at
one specialist centre. In addition, information was collected to explore
any association between the clinical features of these boys and the
results from endocrine and genetic investigations.
Methods
Patients
All boys with a conﬁrmed or presumed 46, XY karyotype who were
reviewed for atypical genitalia by the Glasgow DSD clinic between January
2010 and December 2015 were included in the analysis. Boys with isolated
unilateral undescended testis on clinical examination were excluded.
Detailed phenotypic information was recorded to calculate an external
masculinization score (EMS) (Ahmed et al., 2000b) to objectively docu-
ment the degree of masculinization of the infant’s genitalia.
Endocrine analysis
The following hormone levels were measured at baseline or following
hCG stimulation test: anti-Müllerian Hormone (AMH) using Beckman Gen
11 ELISA, Androstenedione (A) and Testosterone (T) by LC MS/MS using
Water Xevo TMS and Dihydrotestosterone (DHT) by LC/MS/MS using a
Waters mass spectrometer. FSH and LH were measured on the Abbott
Architect ci1600 using chemiluminescent microparticle immunoassays
(Abbott Laboratories Diagnostics, Santa Clara, CA, USA). The hCG stimu-
lation test was performed as described previously (Dixon et al., 2007)
where 1500 units of intramuscular hCG was administered on three con-
secutive days followed by testosterone, dihydrotestosterone and andro-
stenedione levels being recorded on Day 4. For some children this was
followed by hCG stimulation using 1500 units on 2 days of the week over a
2-week period with testosterone levels being measured on Day 22.
Testosterone response was reported as normal if the absolute testoster-
one concentration level increased by two or more times the baseline, or
was above the upper limit of prepubertal range (Ahmed et al., 2016).
Genetic analysis
DNA was extracted from peripheral blood samples using standard meth-
ods for patients undergoing routine clinical genetic testing. Chromosomal
abnormality was identiﬁed by karyotypes or array-CGH. Analysis of seven
DSD associated genes including SRY, AR, NR5A1, HSD17B3, MAMLD1,
NR0B1 and SRD5A2 was performed. All coding exons and ﬂanking intronic
regions (±30 bp) of these seven DSD genes were sequenced using stand-
ard Sanger sequencing. In addition, Multiplex Ligation-dependent Probe
Ampliﬁcation was performed to detect larger deletions and duplications.
Pathogenicity of detected variants was determined using Alamut Visual
version 2.7.1 (Interactive Biosoftware, Rouen, France). Array-CGH was
performed using CytoChip Oligo ISCA 8 × 60 K v2 array (with genome
build numbers GRCh 36, 37, 38 and 39 with majority of cases being
GRCh37). CNVs were validated using CytoChip Oligo ISCA 4 × 180 K.
Duplications and deletions were conﬁrmed by ﬂuorescence in situ hybrid-
ization. Array-CGH analysis was performed using BlueFuse Multi v2.3 or
v2.5 software (Illumina, Inc., San Diego, CA, USA) with CytoChip v2 algo-
rithm. Any abnormal ﬁndings were compared with data held in the
Database of Genomic Variants (http://dgv.tcag.ca/dgv/app/home?ref),
DECIPHER (Cambridge, UK, https://decipher.sanger.ac.uk/) and the
local database of variants. For all CNVs, the following databases were
searched for information: NCBI including PubMed, OVID, Science Direct,
Google Scholar, DECIPHER Ensembl Resources and GeneCards Human
Gene Database. Search terms included the CNVs followed by ‘disorders
of sex development’, ‘DSD’ and the phenotype of the boy from whom the
CNVs was identiﬁed, for example ‘hypospadias’.
Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics 21 (Portsmouth,
UK) and Minitab 17 Statistical Software Minitab, Inc. (Coventry, UK), and
signiﬁcance threshold was set at P < 0.05. Descriptive statistics were used
to assess the distribution of data and all assumptions were assessed prior
to inclusion of output. Mann–Whitney U tests were used for inter-group
comparisons. To test association between variables, Pearson Chi-square
test and linear-by-linear Chi-square test for trend were used.
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Results
Cohort description
A total of 122 boys were identiﬁed with a presumed 46, XY karyotype
(n, 42) or a deﬁnite 46, XY karyotype (n, 80). Median age at evaluation
was 1.33 years (range 0.01–16.42) and this reﬂected the age at pres-
entation to the specialist endocrine service. The phenotype of boys
presenting to the service varied from isolated bilateral undescended
testes (n, 41), isolated hypospadias (n, 33), isolated micropenis (n, 6)
to a variable combination of all the above features (n, 42)
(Supplementary Table S1). In the group of boys with isolated hypospa-
dias, 25 were proximal, 4 were mid-shaft with the remaining 4 being
distal and in the group of boys with a combination of features, 31 had
hypospadias and of this group 26 had proximal hypospadias, 2 had
mid-shaft and the remaining 3 boys had distal hypospadias. The median
EMS of the cohort was 9 (1–11). An associated abnormality was identi-
ﬁed in 39 (32%) boys with 14 (11%) having been diagnosed with a
recognized syndrome (Supplementary Table S1). A family history of
DSD was present in 16 (13%) boys and parental consanguinity was evi-
dent in 3 (2%). All 122 boys had endocrine investigations and 83 (68%)
had an hCG stimulation test. Of the 122 boys, 76 (62%) also had gen-
etic investigations with a total of 43 (35%) boys having array-CGH and
61 (50%) boys having gene panel analysis performed.
Endocrine analysis
Results of the hCG stimulation test were available for 83 boys with
baseline androgen measurements available in an additional 38 boys. Of
the 121 boys who had available results, an endocrine abnormality was
present in 28 (23%) (Fig. 1). The median EMS of the boys with an
endocrine abnormality and those without an endocrine abnormality
was 8.3 (1–10.5) and 9 (1.5–11) (P = 0.028) respectively. Endocrine
abnormalities pointed to a DGD in 19 (16%), luteinising hormone deﬁ-
ciency (LHD) in 5 (4%) and a DAS in 4 (3%). In the remainder who
had normal endocrine investigations, there was one boy who had a
cloacal anomaly, two (2%) boys who had a disorder of Müllerian devel-
opment (DMD) and 90 (74%) boys had a non-speciﬁc disorder of
under-masculinization (NSDUM) with normal gonadal function (Fig. 1).
Genetic analysis
Of 43 boys (NSDUM, 30; DGD, 10; LHD, 3) who had array-CGH
(Supplementary Table S1), CNVs were identiﬁed in 13 (30%)
(NSDUM, 8; DGD, 5). The median EMS of the boys who had array-
CGH performed was 9 (1.5–11); in those who did not have array-
CGH testing, the EMS was also 9 (1–11). The median EMS of the boys
who were found to have CNVs was 8.5 (1.5–11) compared to a
median EMS of 9 (3–11) in the 30 boys who had a normal array-CGH
(P = 0.598). One CNV was termed ‘likely pathogenic’ by the clinical
diagnostic team, two CNVs were termed ‘likely benign’ and the CNVs
in the remaining 10 boys were determined to be of ‘uncertain clinical
signiﬁcance’. Genes within the areas of deletions and duplications
where CNV were identiﬁed are provided in Supplementary Table S2.
Of these 43 boys who had array-CGH analysis, an associated abnor-
mality was found in 11/13 (85%) of the boys in whom CNVs were
identiﬁed and in 15/30 (50%) of boys who were found to have normal
array-CGH (P = 0.033). Of the 61 boys (NSDUM, 41; DGD, 15; DAS,
2; DMD, 2; Cloacal Anomaly, 1) who had the limited seven-gene panel
analysis, variants were identiﬁed in 6 (10%) (NSDUM, 3; DGD, 1;
LHD, 2) with a median EMS of 6 (3, 9). The median EMS of the boys
who had normal gene panel analysis was 9 (1.5–10) and was not signiﬁ-
cantly different to that in the boys where a gene variant was found
(P = 0.312). There were three boys who had single gene analysis per-
formed prior to availability of the gene panel in Glasgow, the median
EMS of these boys was 8 (1–9) and all three boys had a single gene
variant detected. For further details of genetic abnormalities identiﬁed,
refer to the detailed section below and Table I.
Disorders of gonadal development
Endocrine evaluation in 19 of 121 (16%) boys revealed a pattern con-
sistent with a DGD. Median EMS of the 19 boys was 9 (3–10.5) and a
family history of DSD was present in ﬁve cases. Of the 19 boys, 2 boys
had bilateral anorchia. Median (range) serum AMH, FSH, LH and
hCG-stimulated testosterone were 79.2 pmol/l (<0.4–268), 8.3 U/L
(1.6–196.4), 4.8 U/l (1.1–39.1) and 0.8 nmol/l (<0.5–4.7), respect-
ively. Additional abnormalities were found in nine (47%) boys with
three boys having a diagnosis of a recognizable syndrome. Of the 19
boys, 10 had array-CGH and gene panel analysis with a further 5 cases
having gene panel analysis only. Of the 10 cases who had array-CGH
analysis, CNVs were identiﬁed in 5 (50%) and of the 15 cases that had
gene panel testing, a pathogenic NR5A1 variant was identiﬁed in 1 (7%)
boy.
Luteinizing hormone deﬁciency
Of 121 boys who had endocrine investigations, 5 (4%) boys with a
median EMS of 8 (6–9) were found to be LH deﬁcient. Median (range)
serum AMH, LHRH-stimulated FSH, LHRH-stimulated LH and hCG-
stimulated testosterone were 50.6 pmol/l (21.8–686), 4.3 U/l (<0.1–
8.6), 0.9 U/l (<0.1–2.3) and 0.7 nmol/l (<0.5–1.0), respectively. Of
these ﬁve boys, four had associated abnormalities. A diagnosis of
CHARGE syndrome was made in three boys, with mutations in CHD7
found in two of these boys. There was no family history of DSD for
any of these ﬁve boys. Genetic investigations were performed in three
boys. All three had array-CGH performed with two boys having add-
itional gene panel analysis and all of these genetic investigations were
found to be normal in all three boys.
Disorder of androgen synthesis
The median EMS of the four boys diagnosed with 5α-reductase type 2
deﬁciency (5-ARD) was 4 (1, 9) and a family history of DSD was
known in two boys. There were no associated abnormalities in this
group. Pathogenic SRD5A2 variants were identiﬁed in two boys who
had single gene sequencing due to a family history of 5-ARD. In add-
ition, pathogenic SRD5A2 variants were also identiﬁed in two boys
who had routine panel testing without any clear evidence of biochem-
ical abnormalities at evaluation. In one of these boys, urinary steroid
analysis by GCMS had not identiﬁed an endocrine abnormality on ini-
tial testing when performed at the age of 2 days, however, when
repeated at the age of 6 years following molecular conﬁrmation of 5-
ARD, urinary steroid analysis was clearly abnormal.
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Disorder of Müllerian development
Of the 93 boys who had normal biochemistry, 2 boys with a median
EMS of 10 (9–11) were found to have Müllerian structures present on
ultrasound investigation and surgical exploration. Neither of these
boys had other associated abnormalities or a family history of DSD.
One boy underwent targeted DNA analysis for variants in AMH, which
revealed compound heterozygous mutations.
Non-speciﬁc disorder of under-
masculinization
The largest subgroup of boys identiﬁed included boys who had normal
endocrine investigations. Of these 90 boys with NSDUM, a 46, XY
karyotype was conﬁrmed in 66 (73%) boys and the median EMS was 9
(1.5–11). Associated abnormalities were identiﬁed in 26 (29%) boys
with a recognized syndrome being diagnosed in 8 (9%). In 2 of the 90
(2%) boys, there was a positive history of parental consanguinity, and a
family history of DSD was identiﬁed in 11 (12%). Array-CGH was per-
formed in 33 boys and a CNV was detected in 10 (30%) of cases. A
likely benign CNV was identiﬁed in one boy and the remaining nine
cases were deemed to be of uncertain clinical signiﬁcance. Gene panel
analysis was performed in 45 (50%) boys, with a pathogenic variant
detected in SRD5A2 in 1 boy and a pathogenic variant detected in
NR5A1 in 2 boys.
Predicting the likelihood of identifying
a genetic or endocrine abnormality
The presence of an associated abnormality was signiﬁcantly associated
with the likelihood of detecting CNVs on array-CGH analysis (P =
0.033) since 11/26 (43%) of these cases who had array-CGH also had
an associated microdeletion or microduplication. Abnormal endocrine
investigations, however, were not a predictor of detecting a CNVs. In
the 13 boys who had CNVs identiﬁed, 5 (38%) were found to have
abnormal endocrine investigations, and in the 30 boys who had normal
46, XY DSD
N = 122
Abnormal 
Endocrine 
Investigations
N = 28
Normal 
Endocrine 
Investigations
N = 93
Incomplete 
information 
N = 1
NSDUM
N = 90
DMD
N = 2
LHD
N = 5
DGD
N = 19
DAS
N = 4
Cloacal
Anomaly
N = 1
46, XY DSD
N = 121
Figure 1 Consort diagram of 46, XY DSD boys who attended Glasgow DSD service between January 2010 and December 2015 for an assessment
of atypical genitalia. Abbreviations: NSDUM, non-speciﬁc disorder of under-masculinization; DMD, disorder of Müllerian development; DGD, disorder
of gonadal development; LHD, luteinising hormone deﬁciency; DAS, disorder of androgen synthesis.
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array-CGH results, 8 (37%) were found to have abnormal endocrine
investigations (P = 0.439). EMS was not signiﬁcantly associated with
detection of CNVs with a median EMS of 8.5 (1.5, 11) in the boys who
had a CNV detected and 9 (3–11) in the group who had a normal array-
CGH (P = 0.596). The likelihood of identifying pathogenic variants on
gene panel analysis in those cases with abnormal biochemistry (P =
0.26), associated abnormality (P = 0.475) or a low EMS (P = 0.2) did
not reach statistical signiﬁcance. The median EMS of boys who had
.............................................................................................................................................................................................
Table I Genetic abnormalities identiﬁed in 21 46, XY DSD boys.
Subject
Ref
Endocrine
result
EMS Associated malformation Single gene abnormality CNV Additional
genetic tests
performed
72 NSDUM 1.5 DD, Dysmorphic features Not identiﬁed Dup 7q36.3 - US No
128 NSDUM 3 None Compound Heterozygous SRD5A2 c.[16 C >
T];[680 G > A] p.[(Gln6*)];[(Arg227Gln)]
Not analysed No
86 NSDUM 3 Capillary haemangioma on head,
skull abnormality
Heterozygous NR5A1 c.[1379 A > T];[=]
p.[(Gln460Leu)];[(=)]
Dup 2p16.3 - US No
82 NSDUM 6 Dysmorphic features and
microcephaly
Not identiﬁed Dup 16p11.2 - LB No
24 NSDUM 9 None Not analysed Del 7q34 - US No
25 NSDUM 9 None Heterozygous NR5A1 c.[185 G > T];[=]
p.[(Arg62Leu)];[(=)]
Not analysed No
56 NSDUM 9 LD, focal seizures Not identiﬁed Del 1q31.1, Del
5p14.3, Dup
13q32.1 - US
No
69 NSDUM 9 DD, speech delay Not identiﬁed Dup 15q11.1 - US FRAXA—normal
121 NSDUM 9 LD, thickened soft tissues Not analysed Del 11p11.2 - US N
99 NSDUM 11 DD, bilateral retinal coloboma,
Right iris coloboma, visual
impairment
Not analysed Del 20p13 - US N
65 DGD 3 Dysmorphic features, short
stature, LD, panhypopituitarism
Not identiﬁed Del 12q13.12 - US N
28 DGD 6 DD, microcephaly and Fallot’s
tetralogy
Not analysed Del 2p.22.3 - LB 22q11.2—normal
40 DGD 7.5 Encephalocoele, unilateral renal
agenesis
Not identiﬁed Del 4q13.3, Del
16p12.2, Dup
20p12.3
NPHP1—normal
91 DGD 8.5 DD, short stature Not identiﬁed Dep 18q21.32 - LP No
132 DGD 9 None Not identiﬁed Dup 11q11q - US No
90 DGD 9 Aspergers and Autism spectrum
disorder
Heterozygous NR5A1 c.[1019 C > T];[=]
p.[(Ala340Val)];[(=)]
Not analysed No
58 DAS 1 None Compound heterozygous SRD5A2 c.[698 +
1 G > T];[737 G > A] p.[(?)];[(Arg246Gln)]
Not analysed No
38 DAS 3 None Compound Heterozygous SRD5A2 c.[698 +
1 G > T];[737 G > A] p.[(?)];[(Arg246Gln)]
Not analysed No
45 DAS 8 None SRD5A2 (phase unknown) c.268 C > T(;)
307 C > T p.(His90Tyr)(;)(Arg103*)
Not analysed No
76 DAS 9 None Heterozygous SRD5A2 c.[548-2 A > C];[=]
p.[(?)];[(=)]
Not analysed No
1 DMD 9 None Compound Heterozygous AMH c.[500 A >
G]; [1669 T > A] p.[(Tyr167Cys)];
[(Cys557Ser)]
Not analysed No
Details of the genetic abnormalities identiﬁed in 46, XY DSD boys who were investigated by the Glasgow DSD service. Of the 76 boys who had genetic investigations performed, 20
boys were found to have either a single gene abnormality or CNV identiﬁed, and one boy had both a single gene and an array-CGH abnormality. Phenotypic information as well as
the results of endocrine investigations are provided to demonstrate the variation in presentation of boys with genetic abnormalities identiﬁed.
Abbreviations: CNV, copy number variant; NSDUM, non-speciﬁc disorder of under-masculinization; DGD, disorder of gonadal development; DAS, disorder of androgen synthesis;
DMD, disorder of Müllerian development; EMS, external masculinization score; DD, developmental delay; LD, learning difﬁculties; Dup, duplication; Del, deletion; US, uncertain clin-
ical signiﬁcance; LB, likely benign; LP, likely pathogenic.
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normal endocrine investigations was 9 (1.5–11) and was higher than that
in boys who had an endocrine abnormality at 8.3 (1–10.5) (P = 0.028).
Discussion
This study describes in detail the likelihood of detecting an endocrine
or a genetic abnormality in a cohort of 46, XY boys who present to a
multidisciplinary service for an assessment of atypical genitalia. In this
cohort, endocrine investigations were abnormal in about a quarter
whilst genetic analysis revealed an array-CGH abnormality in 30% and
a single gene disorder in almost 15%. This large, well-characterized
group of boys also highlighted the diverse presentations of boys with
atypical genitalia with almost a third of boys having an additional mal-
formation and similar to what has been reported in large multicentre
cohorts (Cox et al., 2014). Neurocognitive abnormalities are often
associated with DSD (Gazdagh et al., 2016) and this was also observed
in the current study.
The comprehensive approach used in the current study has high-
lighted that genetic abnormalities and endocrine abnormalities do not
always associate with each other. Over three-quarters of boys investi-
gated had normal endocrine investigations and of those who also had
molecular genetics and array-CGH analysis, a genetic abnormality was
found in 20%. In those with an abnormal endocrine investigation, over
two-thirds had an abnormality consistent with a primary DGD. Of this
group of 19 boys with a DGD, only one had a molecular genetic
abnormality whilst 50% of those who had array-CGH displayed a
CNV. On the other hand, of the rest of the boys who had normal
endocrine investigations, 30% of those who had array-CGH displayed
a CNV and about 10% of boys who had a limited gene panel had an
abnormal ﬁnding.
The overall CNV detection rate of 30% in this group of boys is com-
parable to previous reports (Tannour-Louet et al., 2010; Baetens
et al., 2014). As expected, the presence of an associated abnormality
was a strong predictor of identifying a CNV, emphasizing the value of
careful examination for the presence of associated malformations in
boys with 46, XY DSD. Three-quarters of the CNVs identiﬁed in this
cohort were clinically classiﬁed as being of uncertain signiﬁcance, how-
ever, on detailed database review half had been previously reported in
cases associated with a DSD. This mismatch highlights the need for
diagnostic services to allocate further expert resources to interpret-
ation of genetic ﬁndings.
The overall yield of molecular genetic abnormalities of approxi-
mately 15% of boys was lower than previous reports (Eggers et al.,
2016; Alhomaidah et al., 2017). However, the likelihood of identifying
a gene defect may be inﬂuenced by the strategy that is adopted for
undertaking molecular genetic analysis. For instance, a targeted gene
analysis approach may yield more variants when selecting cases that
have a clear defect of androgen synthesis (Morel et al., 2011; Eggers
et al., 2016). Identiﬁcation of a genetic abnormality in AR may have
been higher in the past when cases were selected by studying AR bind-
ing (Ahmed et al., 2000a). A recent study in boys with 46, XY DSD
also suggests that the likelihood of ﬁnding a genetic mutation may also
depend on the prevalence of consanguinity (Ozen et al., 2017).
However, the current study clearly shows that molecular genetic
abnormalities may also be evident in cases with apparently normal
androgen synthesis. Disorders of testosterone biosynthesis such as
17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) deﬁciency or
5α-reductase type two deﬁciency (5-ARD) are characterized by a
reduction in conversion of androstenedione (A) to testosterone (T) or
testosterone to dihydrotestosterone (DHT), respectively. Typically,
these conditions are associated with an alteration in the ratio of the
two forms of androgens so that 17β-HSD3 deﬁciency is associated
with a low T:A ratio (Ahmed et al., 2000c) and 5-ARD is associated
with a high T:DHT ratio (Saenger et al., 1978). However, a low T:A
ratio may not be very sensitive (Lee et al., 2007) or speciﬁc (Ahmed
et al., 2000c) for 17β-HSD3 deﬁciency and the T:DHT ratio may not
be sufﬁciently sensitive for identifying cases of 5-ARD (Ng et al., 2000;
Maimoun et al., 2011). The hCG stimulation test which is frequently
used to assess androgen synthesis and testicular function in prepuber-
tal boys remains a controversial test when it comes to deﬁning a nor-
mal response, given that the response may vary depending on the
regimen and the developmental age of the child (Dixon et al., 2007).
Furthermore, molecularly conﬁrmed cases of androgen insensitivity
syndrome who would be expected to have normal androgen synthesis
may show a poor response on hCG stimulation (Ahmed et al., 1999).
Others have suggested that selecting cases by the extent of under-
masculinization may lead to a higher likelihood of genetic abnormalities
(Su et al., 2015). However, the current study shows that a large pro-
portion of cases with a genetic abnormality were not particularly
under-masculinized.
A notable limitation of the study was the evolution of the strategy for
genetic analysis over the study period. Although the endocrine evalu-
ation of this cohort followed as much as possible the guidance proposed
by recent expert groups (Ahmed et al., 2016), the extent of genetic
investigations which were performed in this group of boys was variable
and dependent on the availability of the genetic tests. The seven-gene
panel for XY DSD became available in Glasgow in 2014 with a subse-
quent lowering of threshold for genetic investigations. Similarly, the avail-
ability of array-CGH increased in recent years with testing often being
performed where there were associated abnormalities. It is clear that
variation in several other candidate genes may lead to XY DSD (Eggers
et al., 2016; Alhomaidah et al., 2017) and the gene panel reported in this
study has its obvious limitations. With respect to molecular genetic test-
ing, our strategy has been to incorporate the genetic testing into our
clinically accredited hospital diagnostic laboratory rather than a research
laboratory and as recommended by the UK DSD taskforce (Ahmed
et al., 2016). This strategy is expected to extend to the development of
a larger panel of genes as expert centres increasingly adopt Next
Generation Sequencing (NGS) technology for routine diagnostics
(Baxter et al., 2015; Eggers et al., 2016; Ozen et al., 2017).
In addition, the algorithmic approach that has often been recom-
mended in the past when genetic tests were performed to conﬁrm the
biochemical ﬁndings (Hughes et al., 2012; Ahmed et al., 2013) may
also change. It is increasingly debatable whether this stepwise
approach remains appropriate. In a recent survey of expert centres in
the I-DSD Registry, approximately half of the respondents opted for a
genetic rather than a biochemical test for diagnosing 5-ARD and 17β-
HSD deﬁciency and many would pursue a genetic diagnosis irrespect-
ive of the results of the endocrine investigations (Kyriakou et al.,
2016). Whilst there are clear perceived advantages of adopting a non-
selective NGS-based approach with identiﬁcation of a larger number
of genetic variants (Eggers et al., 2016), a concern remains about the
functional relevance of these genetic variants identiﬁed subsequently
and it is possible that, in the future, the place for biochemical
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evaluation may be to conﬁrm or refute the functional relevance of a
molecular genetic ﬁnding as well as for long-term monitoring following
a genetic diagnosis. Given that a number of cases may have an endo-
crine abnormality but no clear genetic abnormality, perhaps the most
pragmatic approach is to perform both endocrine and genetic investi-
gations in parallel, rather than in a stepwise manner but within the
framework of an expert multidisciplinary diagnostic team (Alhomaidah
et al., 2017).
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